Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part D Enters Phase 2: Land Rush Gives Way to Claim Jumping

This article was originally published in RPM Report

Executive Summary

UnitedHealth and Humana are the runaway winners in the rush to enroll Medicare beneficiaries in private drug plans. Now they have to fight to hold onto their turf.

You may also be interested in...

Not So Random Selection: Medicare Agency Cuts "Churn" In Part D Enrollment

One of the Obama Administration's first moves in managing the Medicare Part D benefit is to tamp down on the number of beneficiaries who will be randomly assigned to a new plan on Jan. 1. Stability is good for the program politically, but it may also be a sign of more hands-on management by the Medicare agency in the years ahead.

The Threat of Reconciliation: Remembering the Part D Vote

Democrats are threatening to use a budgetary procedure to accelerate the passage of broad health reforms in the next Congress. Republicans are already voicing protest, particularly with the idea of a new government-run insurance plan gaining momentum. But those concerns may fall on deaf ears.

iDoc: E-Prescribing Gains Momentum, But Roadblocks Remain

New e-prescribing standards under Medicare Part D were finalized in April, but doctors aren't rushing to swap their pen and pad for a PDA. However, a bill floating through Congress may jumpstart adoption of the technology by doctors--if the legislation can get into this year's Medicare bill.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts